<!DOCTYPE html>
<html lang="en" data-theme="light">
<head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1315&amp;path=livereload" data-no-instant defer></script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bio-Path Holdings Advances RNAi Therapeutics with Promising Treatments for Cancer and Metabolic Diseases - Building Texas Show News</title>
    
    
    <meta name="description" content="Bio-Path Holdings innovates with DNAbilize® platform, advancing RNAi therapeutics for cancer and metabolic diseases, offering new hope for patients.">
    <meta name="keywords" content="news, breaking news, current events, analysis, journalism">
    <meta name="author" content="Building Texas Show">
    
    
    <meta property="og:title" content="Bio-Path Holdings Advances RNAi Therapeutics with Promising Treatments for Cancer and Metabolic Diseases - Building Texas Show News">
    <meta property="og:description" content="Bio-Path Holdings innovates with DNAbilize® platform, advancing RNAi therapeutics for cancer and metabolic diseases, offering new hope for patients.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="http://localhost:1315/posts/2025-06-18-bio-path-holdings-advances-rnai-therapeutics-with-promising-treatments-for-cancer-and-metabolic-diseases/">
    
    <meta property="og:image" content="https://cdn.newsramp.app/reportable/newsimage/98521815a2c4c4b374aee6db5a4f09e0.png">
    
    
    
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Bio-Path Holdings Advances RNAi Therapeutics with Promising Treatments for Cancer and Metabolic Diseases - Building Texas Show News">
    <meta name="twitter:description" content="Bio-Path Holdings innovates with DNAbilize® platform, advancing RNAi therapeutics for cancer and metabolic diseases, offering new hope for patients.">
    
    
    <link rel="canonical" href="http://localhost:1315/posts/2025-06-18-bio-path-holdings-advances-rnai-therapeutics-with-promising-treatments-for-cancer-and-metabolic-diseases/">
    
    
    <link href="https://cdn.jsdelivr.net/npm/daisyui@4.12.10/dist/full.min.css" rel="stylesheet" type="text/css" />
    <script src="https://cdn.tailwindcss.com"></script>
    
    
    <style>
         
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
         
        :root {
          --primary: #0f766e;  
          --primary-content: #ffffff;
          --secondary: #64748b;
          --accent: #dc2626;  
          --neutral: #0f766e;  
          --base-100: #ffffff;
          --base-200: #f8fafc;
          --base-300: #e2e8f0;
          --base-content: #1f2937;
          --teal-600: #0d9488;
          --teal-700: #0f766e;
          --teal-800: #115e59;
        }

         
        [data-theme="light"] {
          --primary: #0f766e;
          --primary-content: #ffffff;
          --secondary: #64748b;
          --accent: #dc2626;
          --neutral: #0f766e;
          --base-100: #ffffff;
          --base-200: #f8fafc;
          --base-300: #e2e8f0;
          --base-content: #1f2937;
          background-color: #ffffff;
          color: #1f2937;
        }

         
        html, body {
          font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
          background-color: inherit;
          color: inherit;
          line-height: 1.6;
        }

         
        main {
          background-color: #a5f3fc;
          color: #1f2937;
          min-height: calc(100vh - 200px);
        }

         
        .content-card {
          background: rgba(255, 255, 255, 0.95);
          color: #1f2937;
          border-radius: 8px;
          box-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
        }

         
        h1, h2, h3, h4, h5, h6 {
          font-weight: 600;
          line-height: 1.3;
        }

         
        .btn-primary {
          background-color: #0f766e;
          border-color: #0f766e;
          color: white;
        }

        .btn-primary:hover {
          background-color: #0d9488;
          border-color: #0d9488;
        }

         
        a {
          color: #0f766e;
          text-decoration: none;
        }

        a:hover {
          color: #0d9488;
        }

         
        .nav-hover:hover {
          background-color: var(--primary) !important;
          color: var(--primary-content) !important;
        }

        .dropdown-content {
          background-color: var(--base-100) !important;
          border: 1px solid var(--base-300) !important;
        }

        .dropdown-item:hover {
          background-color: var(--primary) !important;
          color: var(--primary-content) !important;
        }

        .group:hover .group-hover\:block {
          display: block !important;
        }
    </style>
    
</head>
<body class="min-h-screen bg-base-100">
    
<div class="bg-white border-b border-gray-200">
  <div class="container mx-auto px-4 py-4">
    <div class="flex items-center justify-between">
      
      <a href="/" class="flex items-center">
        <img
          src="https://newswriter.ai/logo.svg"
          alt="Newswriter.ai"
          class="h-8 w-auto"
        />
        <span class="text-sm text-gray-500 ml-3"
          >Let AI Write Your Press Release</span
        >
      </a>

      
      <div class="relative">
        <div class="dropdown dropdown-end">
          <div tabindex="0" role="button" class="btn btn-primary">
            Write My Press Release
            <svg
              class="w-4 h-4 ml-1"
              fill="none"
              stroke="currentColor"
              viewBox="0 0 24 24"
            >
              <path
                stroke-linecap="round"
                stroke-linejoin="round"
                stroke-width="2"
                d="M19 9l-7 7-7-7"
              ></path>
            </svg>
          </div>
          <ul
            tabindex="0"
            class="dropdown-content menu bg-base-100 rounded-box z-[1] w-52 p-2 shadow"
          >
            <li><a href="#" class="text-sm">Write New Press Release</a></li>
            <li><a href="#" class="text-sm">Improve Existing Release</a></li>
            <li><a href="#" class="text-sm">View Examples</a></li>
            <li><a href="#" class="text-sm">Pricing</a></li>
          </ul>
        </div>
      </div>
    </div>
  </div>
</div>

    
    <main>
        

<div class="container mx-auto px-4 py-8">
  <div class="max-w-4xl mx-auto">
    
    <div class="text-sm mb-6">
      <a href="/" class="text-primary hover:underline">Home</a>
      <span class="text-gray-500 mx-2"> / </span>
      <span class="text-gray-500">Article</span>
    </div>

    
    <div class="mb-8">
      <h1
        class="text-4xl md:text-5xl font-bold text-base-content leading-tight mb-6"
      >
        Bio-Path Holdings Advances RNAi Therapeutics with Promising Treatments for Cancer and Metabolic Diseases
      </h1>

      
      <div class="border-b border-gray-200 pb-6 mb-8">
        <div class="flex items-center text-sm mb-4">
          <span class="text-primary font-semibold"> Building Texas Show News </span>
          <span class="text-gray-400 mx-2"> • </span>
          <span class="text-base-content opacity-70">
            June 18, 2025
          </span>
        </div>

        
        
        <a
          href="https://stonegateinc.reportablenews.com/pr/stonegate-capital-partners-updates-coverage-on-bio-path-holdings-inc-otcqb-bpth-q1-25"
          target="_blank"
          class="inline-flex items-center text-primary hover:text-primary-focus underline font-medium"
        >
          Read Original Article →
        </a>
        
      </div>
    </div>

    
    
    <div class="mb-8">
      <img
        src="https://cdn.newsramp.app/reportable/newsimage/98521815a2c4c4b374aee6db5a4f09e0.png"
        alt="Bio-Path Holdings Advances RNAi Therapeutics with Promising Treatments for Cancer and Metabolic Diseases"
        class="w-full h-96 object-cover rounded-lg shadow-lg mb-8"
      />
    </div>
    

    
    
    <div class="bg-base-200 p-6 rounded-lg mb-8">
      <h2 class="text-2xl font-bold text-base-content mb-4">Summary</h2>
      <div
        class="text-lg leading-relaxed mb-8 prose prose-lg max-w-none"
        style="color: var(--base-content)"
      >
        <p>Bio-Path Holdings, Inc., a clinical-stage biotechnology company, is making strides in the development of RNA interference (RNAi) therapeutics with its proprietary DNAbilize® platform. The company's lead candidate, prexigebersen (BP1001), is in Phase 2 trials for acute myeloid leukemia (AML), with a modified version, BP1001-A, showing promise in Phase 1/1b trials for solid tumors and preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein for blood cancers and solid tumors, while BP1003, a STAT3 inhibitor, is in pre-clinical development for pancreatic cancer. Bio-Path's innovative DNAbilize® technology enhances drug stability and cellular uptake, positioning the company as a pioneer in the field. With strategic relationships, including with The MD Anderson Cancer Center, and a strong IP position, Bio-Path is poised for significant advancements in cancer treatment and metabolic diseases.</p>
      </div>
    </div>
    

    
    <div class="mb-12">
      <h2 class="text-2xl font-bold text-base-content mb-6">Full Article</h2>
      <div
        class="prose prose-lg max-w-none leading-relaxed"
        style="color: var(--base-content)"
      >
        <div class="space-y-4">
          <p class='mb-4'><p>Bio-Path Holdings, Inc., a clinical-stage biotechnology company based in Texas, is at the forefront of developing RNA interference (RNAi) therapeutics that could transform the treatment landscape for diseases such as cancer, obesity, and type 2 diabetes. The company's proprietary DNAbilize® platform utilizes neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while reducing toxicity. This innovative approach represents a significant leap forward in targeted therapy, offering potential benefits over traditional treatments.</p><p>The company's lead drug candidate, prexigebersen (BP1001), is currently undergoing Phase 2 trials for acute myeloid leukemia (AML), with a modified version, BP1001-A, in Phase 1/1b trials for solid tumors. BP1001-A has also shown promise in preclinical studies for obesity and type 2 diabetes, highlighting its potential to address metabolic diseases. Additionally, BP1002, targeting the Bcl-2 protein, is being evaluated for blood cancers and solid tumors, with progress noted in its Phase 1 trial. Bio-Path is further expanding its pipeline with BP1003, a STAT3 inhibitor aimed at pancreatic cancer, following successful preclinical trials.</p><p>Despite facing financial challenges, Bio-Path Holdings' strategic partnerships, including with The MD Anderson Cancer Center, and its robust intellectual property portfolio underscore its potential to lead in the RNAi therapeutics space. The advancements made by Bio-Path not only demonstrate the efficacy of its DNAbilize® technology but also signal a broader impact on the treatment of complex diseases. As the company's drug candidates approach critical milestones, their success could herald a new era of effective, targeted treatments for some of the most challenging medical conditions today, offering hope to patients worldwide.</p></p>
        </div>
      </div>
    </div>

    
    
    <div class="bg-base-200 p-4 rounded-lg mb-8 text-sm text-gray-600">
      
      <p>Article ID: 82969</p>
       
      <p>Feed Item ID: 15174</p>
      
    </div>
    

    
    <div class="text-center">
      <a href="/" class="btn btn-outline btn-lg">← Back to Home</a>
    </div>
  </div>
</div>

    </main>
    
    
<footer class="bg-teal-700 text-white">
  <div class="container mx-auto px-4 py-6">
    <div class="flex flex-col md:flex-row justify-between items-center gap-4">
      <div class="flex items-center gap-4">
        <p class="text-sm">
          Newswriter.ai © 2025 All Rights Reserved
        </p>
        <a href="#" class="text-sm hover:text-teal-200 transition-colors"
          >Privacy Policy</a
        >
        <a href="#" class="text-sm hover:text-teal-200 transition-colors"
          >Terms of Service</a
        >
      </div>

      
      <div class="flex items-center">
        <div
          class="bg-white text-black px-3 py-1 rounded flex items-center gap-2"
        >
          <div class="border-2 border-black rounded px-2 py-1">
            <span class="font-bold text-xs">AI<br />TS</span>
          </div>
          <div class="text-xs">
            <div class="font-semibold">Verified Tool on</div>
            <div class="font-bold">AI Tech Suite</div>
          </div>
          <div class="text-lg">✓</div>
        </div>
      </div>
    </div>
  </div>
</footer>

</body>
</html>
